Tip:
Highlight text to annotate it
X
>> NEUROBLASTOMA IS THE MOST
COMMON CANCER, SOLID TUMOR, IN
CHILDREN.
IT OCCURS IN APPROXIMATELY 7% OF
CHILDREN AND CAUSES
APPROXIMATELY 10% OF ALL DEATHS
THAT OCCUR IN CHILDREN WITH
CANCER.
THE CHALLENGE WITH HIGH-RISK
NEUROBLASTOMA IS TO FIND NEW
TREATMENTS THAT ARE DIFFERENT
FROM THE STANDARD TREATMENTS
THAT WE'VE USED IN THE PAST -
THE CHEMOTHERAPY AGENTS - AND SO
THE TREATMENT WE'RE TALKING
ABOUT, CHIMER 14.18, IS A
DIFFERENT TREATMENT APPROACH;
IT'S A MONOCLONAL ANTIBODY.
MONOCLONAL ANTIBODIES ARE
BIOENGINEERED PRODUCTS, THEY'RE
PROTEINS THAT ARE MANUFACTURED
AND-- AND-- AND ARE ANTIBODIES.
THEY BIND TO SPECIFIC SITES,
CANCER CELLS, AND WHAT
ANTIBODIES, IN PARTICULAR THE
CHIMER 14.18, IS ABLE TO DO, IS
TO BRING THE-- THE BODY'S NORMAL
IMMUNE SYSTEM TO ATTACK THE
CANCER CELLS, AND SO THAT'S THE
BENEFIT OF USING THE MONOCLONAL
ANTIBODY HERE, THE CHIMER 14.18.
THERE WAS A-- NCI HELD A
COMPETITIVE PROCESS TO SELECT A
PHARMACEUTICAL COLLABORATOR.
UNITED THERAPEUTICS OF SILVER
SPRING, MARYLAND WAS SELECTED AS
A COLLABORATOR, AND SO NOW NCI
AND UNITED THERAPEUTICS ARE
WORKING TOGETHER, ALONG WITH THE
RESEARCHERS FROM THE CHILDREN'S
ONCOLOGY GROUP, TO DEVELOP THE
ADDITIONAL DATA THAT ARE NEEDED
TO GO INTO THE BLA SO THAT
CHIMER 14.18 CAN BE COMMERCIALLY
AVAILABLE TO-- FOR CHILDREN WITH
NEUROBLASTOMA.